TBPH Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
20.7M
+17.1%
17.7M
-61.4%
45.9M
+129.6%
20.0M
-23.7%
26.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
20.7M
+17.1%
17.7M
-61.4%
45.9M
+129.6%
20.0M
-23.7%
26.2M
Operating Expenses
29.0M
+6.7%
27.2M
+5.0%
25.9M
-2.1%
26.4M
-8.6%
28.9M
R&D
4.7M
-19.2%
5.8M
-20.8%
7.4M
-9.3%
8.1M
-22.7%
10.5M
SG&A
14.2M
-20.0%
17.7M
-4.3%
18.5M
+1.0%
18.3M
-0.5%
18.4M
Operating Income
-8277000
+12.7%
-9483000
-147.4%
20.0M
+410.0%
-6455000
-136.9%
-2725000
EBITDA
-5418000
+0.9%
-5469000
-126.8%
20.4M
+437.4%
-6050000
-97.4%
-3065000
Net Income
-5898000
-19.6%
-4933000
-108.1%
61.0M
+1588.1%
3.6M
-93.4%
54.8M
EPS (Basic)
$-0.11
-10.0%
$-0.10
-108.3%
$1.20
+1614.3%
$0.07
-93.6%
$1.09
EPS (Diluted)
$-0.11
-10.0%
$-0.10
-108.8%
$1.14
+1528.6%
$0.07
-93.5%
$1.08
Shares (Diluted)
51.7M
+0.8%
51.3M
-4.5%
53.7M
+3.4%
51.9M
+2.3%
50.7M
Theravance Biopharma (TBPH) โ€” Financials